Skip to main content

Table 1 Summary of clinical, immunophenotypic, and cytogenetic data for all six patients

From: IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt’s lymphoma

Case #

Age/Gender

Involved sites at presentation

Immunophenotype

Karyotype 1

FISH 2(% cells)

Therapy 3

Outcome/Follow up

  

Nodal

Extranodal

BCL2

BCL6

CD10

CD38

MUM1

sIg

Ki-67%

    

1

52/M

Paraaortic, pancreatic, portohepatic, cervical, axillary, mediastinal

NA

+

+

-

NA

NA

λ

100

Complex4

IGH x 3 (100%)

IC

DIED/8 Months

2

24/M

Left external iliac

Left femoral neck

+

+

+

NA

+

-

75-80

46,XY

IGH/C-MYC (46%), IGH x 3–4 (51%)

IC, HSCT

DIED/20 Months

3

61/F

NA

Left maxillary sinus

+

+

-

NA

+

κ

100

46,XX

IGH x 3 (20%)

IC, HSCT

ALIVE/105 Months (Multiple Relapses)

4

68/F

Gastrohepatic, periaortic, pericaval, mesenteric

NA

+

+

+

+

NA

κ

95-99

NA

IGH/BCL2 (91.5%), C-MYC x 3–4 (87%), IGH x 3 (42%)

IC

ALIVE/42 Months

5

44/M

NA

Right submandibular space, right lateral neck

+

+

+

+

NA

κ

100

NA

IGH/C-MYC, C-MYC x 3–4, IGH x 3–6, BCL2 x 3–6 (96%)

IC, EBRT

DIED/6 Months

6

4/M

Retroperitoneal, mesenteric

Liver, Omentum

+

+

+

+

NA

κ

95-99

NA

C-MYC x 3 (13%), IGH x 3 (17%)

IC, HSCT

DIED/6 Months

  1. 1Karyotype: standard cytogenetic evaluation performed using G-banding.
  2. 2FISH: performed using the following Abbott Molecular (Des Plaines, Ill) probes: LSI IGH(14q32)/BCL2(18q21) Dual Color, LSI IGH(14q32)/MYC(8q24)/CEP8 Tri-Color Dual Fusion, LSI MYC Dual Color Break Apart (8q24), LSI IGH Dual Color Break Apart (14q32), and LSI TCR alpha/delta Dual Color Break Apart (14q11.2) probes.
  3. 3Therapy: IC, Intensive chemotherapy; HSCT, Hematopoietic Stem Cell Transplant; EBRT, External Beam Radiotherapy.
  4. 4Complex Karyotype for patient 1: 44,X,-Y,add(3)t(3;22)(p25;q12),t(8;14)(q24;q32),-21.